Your browser version may not work well with NCBI's Web applications. More information here...
1: Eur J Biochem. 2004 Apr;271(8):1516-24.Click here to read Links

Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.

Department of Biology, Georgia State University, PO Box 4010, Atlanta, GA 30302-4010, USA.

The crystal structures of the wild-type HIV-1 protease (PR) and the two resistant variants, PR(V82A) and PR(L90M), have been determined in complex with the antiviral drug, indinavir, to gain insight into the molecular basis of drug resistance. V82A and L90M correspond to an active site mutation and nonactive site mutation, respectively. The inhibition (K(i)) of PR(V82A) and PR(L90M) was 3.3- and 0.16-fold, respectively, relative to the value for PR. They showed only a modest decrease, of 10-15%, in their k(cat)/K(m) values relative to PR. The crystal structures were refined to resolutions of 1.25-1.4 A to reveal critical features associated with inhibitor resistance. PR(V82A) showed local changes in residues 81-82 at the site of the mutation, while PR(L90M) showed local changes near Met90 and an additional interaction with indinavir. These structural differences concur with the kinetic data.

PMID: 15066177 [PubMed - indexed for MEDLINE]

Structures reported by this article

Patient Drug Information

  • Indinavir (Crixivan® )

    Indinavir is used to treat human immunodeficiency virus (HIV) infection in adults. It belongs to a class of drugs called protease inhibitors, which slow the spread of HIV infection in the body. It is usually taken with o...